(redirected from Angiotensin II receptor antagonist)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Angiotensin II receptor antagonist: ACE inhibitor, calcium channel blocker

Accounting Research Bulletins

Recommendations by the American Institute of Certified Public Accountants on how accountants ought to treat certain facts or items. While Accounting Research Bulletins are not authoritative in themselves, the SEC often makes them so by adopting them.


A trader who practices arbitrage. That is, an arbitrageur attempts to profit from inefficiencies in price by making transactions that offset each other. For example, one may buy a security at a low price, and, within a few seconds, re-sell it to a willing buyer at a higher price. Arbitrageurs can keep prices relatively stable as markets attempt to resist their attempts at price exploitation. They often use computer programs because their transactions can be complex and occur in rapid succession.


References in periodicals archive ?
Jimenez, Fast Screening Method for the Determination of Angiotensin II Receptor Antagonists in Human Plasma by High-Performance Liquid Chromatography with Fluorimetric Detection, J.
Bristol-Myers Squibb's pharmaceutical research institute will head the development effort for the angiotensin II receptor antagonist.
5 mg or angiotensin II receptor antagonists and diuretic-Telmisartan 40 mg; 80 mg and Indapamide 1.
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
Whereas, the exclusion criteria included patients having a current diagnosis of type 1 or type 2 diabetes mellitus, patients on antihypertensive therapy or any drug that affects blood pressure, patients with a history of hepatic, cardiac, renal or blood diseases or other diseases which may interfere with the study, patients having hypersensitivity to angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, patients with a history of severe or resistant hypertension, patients with secondary hypertension of any etiology, pregnant or breast feeding women, and patients with serious disorders which may limit the ability to evaluate the efficacy of the trial drugs.
24 October 2011 - The European Medicines Agency (EMA) said in a press release on Thursday that its Committee for Medicinal Products for Human Use (CHMP) had reviewed the possible connection between the use of angiotensin II receptor antagonists (ARBs) and the occurrence of new cancers and concluded that the evidence does not support any increased risk of cancer in patients using these medicines.
There is need to test a potential additive effect of a low protein diet in combination with angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists or other antiproteinuric medications.

Full browser ?